BR0110034A - Inibidores do transporte de fosfatos - Google Patents

Inibidores do transporte de fosfatos

Info

Publication number
BR0110034A
BR0110034A BR0110034-3A BR0110034A BR0110034A BR 0110034 A BR0110034 A BR 0110034A BR 0110034 A BR0110034 A BR 0110034A BR 0110034 A BR0110034 A BR 0110034A
Authority
BR
Brazil
Prior art keywords
transport inhibitors
phosphate transport
phosphate
sulfonamido
aryl
Prior art date
Application number
BR0110034-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Joseph Weinstock
Gerald Girard
Dimitri Gaitanopoulos
Original Assignee
Smithkline Beecham Corporatiio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporatiio filed Critical Smithkline Beecham Corporatiio
Publication of BR0110034A publication Critical patent/BR0110034A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
BR0110034-3A 2000-05-12 2001-05-11 Inibidores do transporte de fosfatos BR0110034A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20399500P 2000-05-12 2000-05-12
PCT/US2001/015324 WO2001087294A1 (en) 2000-05-12 2001-05-11 Phosphate transport inhibitors

Publications (1)

Publication Number Publication Date
BR0110034A true BR0110034A (pt) 2003-05-27

Family

ID=22756167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110034-3A BR0110034A (pt) 2000-05-12 2001-05-11 Inibidores do transporte de fosfatos

Country Status (14)

Country Link
JP (1) JP2003533477A (cs)
KR (1) KR20020093983A (cs)
CN (1) CN1429108A (cs)
AU (1) AU2001261471A1 (cs)
BR (1) BR0110034A (cs)
CA (1) CA2408667A1 (cs)
CZ (1) CZ20023701A3 (cs)
HU (1) HUP0302234A2 (cs)
IL (1) IL152587A0 (cs)
MX (1) MXPA02011160A (cs)
NO (1) NO20025399D0 (cs)
PL (1) PL359931A1 (cs)
WO (1) WO2001087294A1 (cs)
ZA (1) ZA200209106B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378179A (en) * 2001-08-03 2003-02-05 Pantherix Ltd Aromatic sulfonamides and their use in treating bacterial diseases
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX2011007024A (es) 2008-12-31 2011-09-27 Aedelyx Inc Compuestos y metodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrogeno (nhe) en el tratamiento de trastornos asociados con retencion de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
CN103183623A (zh) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 一组苯磺酰胺基苯甲酰胺类衍生物及制备和应用
KR20250026881A (ko) 2013-04-12 2025-02-25 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
US9765050B2 (en) 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment
CN105395532B (zh) * 2015-11-25 2017-11-14 中国医学科学院医药生物技术研究所 2‑苯磺酰胺基苯甲酰胺类化合物在肝损伤保护和肝纤维化防治中的应用
WO2018043400A1 (ja) * 2016-08-30 2018-03-08 日本曹達株式会社 スルホニルアミノベンズアミド化合物および有害生物防除剤
MA47203A (fr) 2017-01-09 2019-11-13 Ardelyx Inc Inhibiteurs d'antiport à médiation par nhe
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
US11390599B2 (en) 2018-06-01 2022-07-19 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146513A0 (en) * 1999-06-24 2002-07-25 Smithkline Beecham Corp Macrophage scavenger receptor antagonists
AR030911A1 (es) * 1999-07-20 2003-09-03 Smithkline Beecham Corp Uso de n-aril-2-sulfonamidobenzamidas para la manufactura de un medicamento para el tratamiento de la insuficiencia renal cronica y composiciones farmaceuticas

Also Published As

Publication number Publication date
JP2003533477A (ja) 2003-11-11
CN1429108A (zh) 2003-07-09
WO2001087294A1 (en) 2001-11-22
NO20025399L (no) 2002-11-11
ZA200209106B (en) 2003-10-23
PL359931A1 (en) 2004-09-06
AU2001261471A1 (en) 2001-11-26
CZ20023701A3 (cs) 2003-11-12
IL152587A0 (en) 2003-05-29
CA2408667A1 (en) 2001-11-22
NO20025399D0 (no) 2002-11-11
HUP0302234A2 (hu) 2003-11-28
KR20020093983A (ko) 2002-12-16
MXPA02011160A (es) 2003-03-10

Similar Documents

Publication Publication Date Title
TR200200112T2 (tr) Fosfat taşıma ihtibitörleri
BR0110034A (pt) Inibidores do transporte de fosfatos
WO2002028353A3 (en) Phosphate transport inhibitors
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
ES2152196T3 (es) Implante para vertebra.
PT883415E (pt) Inalador para medicacao em po
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
BRPI0411924A (pt) métodos e dispositivos para oclusão de lúmens de corpo e/ou para fornecimento de agentes terapêuticos
EP1274444A4 (en) COMPOUNDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS OR DISORDERS CAUSED BY THE ABUSE OF PSYCHOACTIVE SUBSTANCES
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
EE05056B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
PT1255538E (pt) Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros
ES2166816T3 (es) Derivados piridil-imidazolicos y procedimientos para su preparacion.
NO20005548D0 (no) Mykobakterieinhibitorer
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
NO20012777L (no) Anvendelse av riluzol ved behandling av akustiske traumer
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
BR9708037A (pt) Método para o tratamento de abuso de substância
BR9612549A (pt) Método para tratamento de agressão excessiva
EE200200705A (et) Süsteemid ja meetodid limaskesta ravimiseks
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]